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Abstract
Background: To develop a low cost method to screen for virologic failure of antiretroviral therapy (ART) and HIV-1 drug
resistance, we performed a retrospective evaluation of a screening assay using serial dilutions of HIV-1 RNA-spiked blood
plasma and samples from patients receiving .6 months of first-line ART.
Methods: Serial dilution testing was used to assess sensitivity of a simple PCR-based assay (targeted at $1,000 HIV RNA
copies/mL). We created blood plasma minipools of five samples, extracted HIV RNA from the pools, PCR amplified the
reverse transcriptase (RT) coding region of the HIV-1 pol gene from extracted RNA, sequenced PCR product of positive
pools, and used sequences to determine drug resistance. Sensitivity, specificity, and predictive values were determined for
different levels of virologic failure based on maximum viral loads of individual samples within a pool.
Results: Of 295 samples analyzed, 43 (15%) had virologic failure at $50 copies/mL (range 50–10,500 copies/mL, four at
$1,000 copies/mL). The assay demonstrated 100% sensitivity to detect virus from these four samples, requiring only one
round of PCR, and 56% and 89% sensitivity to detect samples with $50 and $500 copies/mL using two rounds. Amplified
PCR products of all positive pools were successfully sequenced and 30% harbored $1 major resistance mutation. This
method would have cost 10% of the combined costs of individual viral load and resistance testing.
Conclusions: We present a novel method that can screen for both virologic failure of first-line ART and drug resistance. The
method is much less expensive than current methods, which may offer sustainability in resource-limited settings.
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Introduction
Where available, routine HIV viral load testing is recommended
to monitor for virologic failure of antiretroviral therapy (ART) [1].
However, commercial viral load assays are expensive and require
sophisticated equipment, technical expertise, and maintenance
that are not feasible in many resource-limited settings. To decrease
the costs of virologic monitoring in these settings, methods
incorporating viral load testing using pooled specimens have been
evaluated in statistical simulations and retrospective analyses.
These methods, which utilize the quantitative results of pooled and
selective individual testing using mathematical formulas to resolve
positive pools, have been shown to increase efficiency of virologic
monitoring and reduce costs using blood plasma specimens and
dried blood and plasma spots, while preserving accuracy to detect
levels of viremia as low as 50 HIV RNA copies/mL [2,3,4,5].
The objective of virologic monitoring is to determine if a patient
with viremia has failed ART due to drug-resistant virus or if first-
line therapy may be salvaged (e.g. by increasing adherence or
eliminating interacting medications). While drug resistance is more
likely with higher levels of viral replication and low levels of
viremia are often due to ‘‘blips’’ [6,7] that carry no long-term
clinical significance, the viral load itself is of limited utility in
making this distinction. In other words, the most important clinical
information is whether or not the patient harbors drug-resistant
virus rather than the actual value of the viral load. Failure without
resistance is usually attributable to problems with adherence. In
resource abundant settings, this distinction is made by performing
drug resistance assays on patient samples with virologic failure.
However, in most resource-limited settings, drug resistance testing
is even less feasible than viral load monitoring due to cost
(US$200–400 per genotyping assay). Therefore, in these settings
where second-line treatment options are limited and maximizing
first-line therapy is of utmost importance, a low-cost assay
designed to allow for detection of virologic failure and evaluation
for drug resistance mutations would likely be more useful clinically
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and do not reliably predict the need for a change in therapy when
unaccompanied by drug resistance data.
In order to lower the costs associated with identifying virologic
failure and drug resistance in the setting of ART, we designed a
platform combining sample pooling with qualitative polymerase
chain reaction (PCR) amplification of the reverse transcriptase
(RT) coding region of the HIV-1 pol gene, and sequencing of the
PCR product for detection of drug resistance mutations. Use of
pooled rather than individual samples decreased assay sensitivity
to a level at which virologic failure was likely (targeting $1,000
HIV RNA copies/mL) and drug resistance could be assessed. We
hypothesized that this method would be useful to screen for both
virologic failure of first-line ART and drug resistance in most
resource-limited settings.
Methods
Ethics Statement
This study was approved by the UCSD Human Research
Protections Program. All participants whose samples were used for
this study signed a written informed consent.
Study population and samples
Testing was performed on pooled patient samples and serial
dilutions of HIV RNA-spiked HIV-negative blood plasma. For
serial dilution testing, a standard solution obtained from the NIH
AIDS Reagent Program with a viral load of 150,000 HIV RNA
copies/mL was used. Serial dilutions were prepared by combining
this solution with HIV-negative blood plasma to obtain samples
with HIV RNA copy numbers of 50, 100, 500, 1,000, and 5,000
copies/mL. These serial dilutions were made in triplicate and
designed to simulate minipools (consisting of five samples)
containing a single specimen of 250, 500, 2,500, 5,000, and
25,000 copies/mL (and four samples with zero copies/mL).
Blood plasma samples collected from participants in the San
Diego Primary HIV Infection Program enrolled between January
1998 and January 2007 were used. These participants had
initiated ART with at least three agents for $6 months (+/22
weeks). Each sample had previously undergone individual
quantitative viral load testing using the ultra-sensitive Amplicor
HIV-1 Monitor viral load assay (Roche Molecular Diagnostics,
Pleasanton, California). Technicians performing the assay were
blinded to patients and viral load results. Multiple samples from
some patients were included because of planned 6-month follow-
up visits, but each of these samples was obtained at a different time
point.
Nucleic acid amplification and resistance testing
Starting volumes of 500 microliters were used for the serial
dilutions and the sample pools that were constructed by combining
100 microliters of 5 individual patient samples. Testing on
minipools of 5 patient samples rather than individual samples
was performed to decrease assay sensitivity to detect individual
patient samples containing $1,000 HIV RNA copies/mL, in
addition to the expected cost savings from pooled testing. A pool
size of 5 was chosen, since it is less technically complex than larger
pool sizes and allows for a sufficient volume of each individual
sample to be included in the pool. RNA extraction was performed
using the QIAmp Viral RNA Purification Spin Protocol (Qiagen,
Valencia, California) with a final elution volume of 50 microliters.
Reverse transcription was performed using the AmbionH RET-
ROscript kit (Applied Biosystems, Foster City, California),
according to the manufacturer’s instructions.
To develop the qualitative pooled RT assay, the PCR protocol
used the following hemi-nested primers in the HIV-1 RT coding
region, which are specific to regions that are conserved across
clades (See Figures S1, S2 and S3).
First round:
CI-POL1 GGAAGAAATCTGTTGACTCAGATTGG (For-
ward)
3RT ACCCATCCAAAGGAATGGAGGTTCTTTC (Re-
verse)
Second round:
5RT AAATCCATACAATACTCCAGTATTTGC (Forward)
3RT ACCCATCCAAAGGAATGGAGGTTCTTTC (Re-
verse)
For the first round of PCR, 10 mL of cDNA product were added
to 40 mL of reaction mixture that consisted of 0.5 mL of Taq
polymerase (Roche), 5 mLo f1 0 6 PCR buffer with magnesium
chloride (Roche), 1 mL of 10 mM dNTPs (Roche), 31.5 mLo f
nuclease-free water, and 1 mL each of the CI-Pol1 and 3RT
primers. The 50 mL solution was then heated to 95uC for
2 minutes, followed by 35 cycles at 95uC for 30 seconds, 50uC
for 30 seconds, and 72uC for 1 minute and a final heating step at
72uC for 10 minutes. For the second round PCR, 5 mL of the first
round PCR product was added to 45 mL of reaction mixture that
consisted of the same reagents and cycling conditions as for the
first round of PCR, except for a slightly larger volume of nuclease-
free water (36.5 mL), and 1 mL each of the 5RT and 3RT primers.
One round of PCR was performed on the serial dilutions of RNA
in spiked HIV-negative blood plasma, and both rounds of PCR
were performed on the minipools. The presence or absence of
PCR product was assessed using agarose gel electrophoresis after
each round. Although this platform is designed for deconvolution
of positive pools by retesting of individual samples included in
pools with detectable PCR product, this was not performed for this
proof-of-principle experiment due to limited stored sample
volumes. The amplified PCR product for each positive pool was
then sequenced using a ‘‘home brew’’ Sanger sequencing
technique, as described elsewhere [8,9]. Sequences were assessed
for resistance associated mutations by entering them into the
Stanford University HIV Drug Resistance Database [10].
Determination of test characteristics
For serial dilution testing, amplifications were performed in
triplicate and repeated, and detectable PCR product was
evaluated at each input viral load level. For the patient samples,
we determined the sensitivity, specificity, and positive and negative
predictive values for the first- and second-round PCR reactions to
detect varying levels of viremia (50, 100, 200, 300, 400, 500, 750
and 1,000 copies/mL) constituting the minipools based on
previous viral load testing of individual samples. Cost savings
were estimated based on the efficiency of the assay at each
threshold and the cost of viral load assays and drug resistance
testing at University of California, San Diego.
Results
For the serial dilutions of RNA in spiked HIV-negative plasma,
first-round PCR product was detected for all replicates with viral
loads of 5,000 and 1,000 HIV RNA copies/mL. For patient
samples, 295 blood plasma samples from 171 patients were
included for 295 unique patient visits. The majority (95%) of the
cohort was male, with a mean age of 37 years (range 21–62 years),
and most (90%) were men who have sex with men (see Table 1).
Based on previous individual quantitative testing, 43 of 295
samples (15%) had detectable HIV RNA ($50 copies/mL),
HIV Treatment and Resistance Test
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Among detectable samples, the viral load ranged from 50 to
10,500 copies/mL, with a median viral load of 231 copies/mL (see
Table 2).
The qualitative pooled RT assay was performed on 59
minipools of 5 patient samples (N=295 samples). Of these, 39
minipools yielded no PCR product after two rounds, 3 yielded
product after the first round, and 17 yielded product only after
both rounds. The assay detected individual samples with $1,000
HIV RNA copies/mL with 100% sensitivity using one or two
rounds of PCR (four samples with 1390, 2038, 4782 and 10,500
copies/mL each). The sensitivities of the first- and second-round
PCR were 9% and 56% to detect samples with $50 copies/mL
and 33% and 89% to detect samples harboring $500 copies/mL.
Negative predictive values were around 90% or higher for both
rounds of PCR to detect $500 copies/mL. The test characteristics
of the pooled RT assay to detect varying levels of virologic failure
in individual samples using one and two rounds of PCR are
displayed in Figures 1 and 2. Screening of these 295 samples for
virologic failure with the pooled RT assay would require 159
assays, including pooled and deconvolution testing, compared to
295 assays with individual testing. The per-assay costs of viral load
and pooled RT assays at UCSD were $97 and $11 (slightly less for
only one round of PCR) respectively. Based on these assay costs,
between $1,752 and $1,775 would have been spent to screen 295
samples for virologic failure using the pooled RT assay, compared
to $28,662 for viral load testing using the Amplicor viral load
assay.
Sequence data for the HIV-1 RT coding region were
successfully generated from each of the 20 positive minipools. Of
these sequences (pools), six (30%) had mutations associated with
low-, intermediate-, and/or high-level resistance to nucleoside or
non-nucleoside reverse transcriptase inhibitors. The most common
mutation was K103N, followed by mutations at positions 184
(M184MV, M184I) and 215 (T215CY, T215Y, T215D) of HIV-1
RT. The cost of sequencing amplified PCR product, including
PCR clean-up, was $87 per sample, compared to around $300 for
commercial genotyping. Therefore, the total cost of sequencing
the PCR product of positive pools using the pooled RT assay
would have been $1,739, compared to $6,000 for commercial
genotyping.
Table 1. Patient demographic data (for n=171 patients).
Demographic Total
Male sex, n (%) 162 (95)
Age, mean in years (range)1 37 (21–62)
Ethnicity, n (%):
White 124 (73)
African American 8 (5)
Latino/a 30 (18)
Asian 6 (4)
Other 3 (2)
HIV Risk Factor, n (%)
MSM 154 (90)
MSM+IDU 3 (2)
Heterosexual 12 (7)
Other 2 (1)
MSM=men who have sex with men; IDU=injection drug users.
1Age was determined at the time of acquisition of the first chronological
sample collected from an individual patient that was included in the analysis.
doi:10.1371/journal.pone.0035401.t001
Table 2. Treatment and laboratory data for samples
(n=295)*.
Variable Total
ART regimen
PI based, n (%) 138 (47)
NNRTI based, n (%) 128 (43)
PI and NNRTI based, n (%) 9 (3)
NRTI only, n (%) 20 (7)
CD4 cell counts at sample acquisition
Median CD4 cell count, median/mL (range) 656 (152–1415)
CD4,200 cells/mL, n (%) 1 (0)
CD4 200–350 cells/mL, n (%) 17 (6)
CD4 350–500 cells/mL, n (%) 52 (18)
CD4.500 cells/mL, n (%) 225 (76)
Viral load
&
Median detectable viral load, copies/mL (range) 231 (50–10,500)
VL,50 copies/mL, n (%) 252 (85)
VL 50–100 copies/mL, n (%) 12 (4)
VL 101–500 copies/mL, n (%) 21 (7)
VL 501–1,000 copies/mL, n (%) 6 (2)
VL.1,000 copies/mL, n (%) 4 (1)
ART=antiretroviral therapy, PI=protease inhibitor, NNRTI=non-nucleoside
reverse transcriptase inhibitor, NRTI=nucleoside reverse transcriptase inhibitor,
VL=viral load.
*Ninety-one (out of 171) patients are represented with multiple samples
(maximum number of samples per patient=3).
&For three samples with missing viral load information values were imputed as
,50 copies/mL based on chronologically close viral load information.
doi:10.1371/journal.pone.0035401.t002
Figure 1. Test characteristics of qualitative pooled RT assay in
the detection of varying levels of virologic failure using first
round of PCR only. PPV=positive predictive value, NPV=negative
predictive value.
doi:10.1371/journal.pone.0035401.g001
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Although quantitative viral load testing on pooled specimens
has shown promise in reducing the cost of virologic monitoring of
ART in resource-limited settings [2,3,4,5], it is still expensive and
does not provide information regarding drug resistance, which is
clinically more useful than the viral load itself. This study
presented a qualitative PCR-based platform that can detect levels
of viremia at which true virologic failure is likely and at which the
presence of drug resistance may be evaluated. Further, this new
platform evaluated the RT coding region of the HIV-1 pol gene
using primers that are conserved across clades, since the vast
majority of first-line ART regimens in resource-limited settings are
comprised of NNRTI and NRTIs. This allows for the PCR
product to be sequenced for the presence of the mutations most
likely to be associated with ART failure in these settings. This
platform, however, can also be adapted to evaluate populations
using protease inhibitor (PI) based therapy by adding an additional
PCR assay using primer sets that cover the HIV-1 pro coding
region.
Unlike quantitative pooling methods [2,3,4,5], the qualitative
nature of the new assay will require that all positive pools must be
resolved by retesting of all individual samples in those pools using
the same PCR assay [11]. Despite this, the pooled RT assay in this
study was much more efficient than individual viral load testing,
requiring just over half of the assays required for individual testing
of the cohort. Although we did not perform deconvolution testing
in real time, we were able to calculate the number of assays needed
based on the pool positivity rate, since all samples in positive pools
would be retested individually. Based on per-assay costs, screening
of these samples using the pooled RT assay would have saved
approximately $26,900 compared to individual viral load testing,
and sequencing of the PCR product would have saved an
additional $4,260 compared to commercial genotyping. There-
fore, even in populations with higher rates of virologic failure for
which relative efficiency of pooled testing would be lower in terms
of the total number of assays needed, the cost of monitoring for
virologic failure and drug resistance would still be significantly
lower than that of commercial viral load testing and genotyping.
For example, even in populations with virologic failure rates up to
30%, this assay would likely cost no more than 25% of standard
methods. However, a full cost-effectiveness analysis was not
performed in this retrospective study, and future studies should
evaluate the real-time costs of assays, equipment maintenance,
decontamination processes, and quality assurance measures in
resource-limited settings to further evaluate feasibility of this
method. Nevertheless, this potential cost savings in areas with
limited second-line therapeutic options and high disease burden
could then allow for more informed decisions regarding when to
switch and which antiretroviral drugs are no longer efficacious.
Further, our platform detected all samples with $1,000 HIV
RNA copies/mL with negative predictive values of 100%, even
when only one round of PCR was performed, and requiring only
one round of PCR would greatly decrease the complexity and cost
of the assay. One round of PCR also offered an advantage over
two rounds with respect to positive predictive value, although
three pools with drug resistance mutations were only identified
after two (not after one) round of PCR. Due to the qualitative
nature of the assay, it was not possible to differentiate between
samples that had lower and higher viral loads. At higher threshold
levels for virologic failure, the false positive rate increased (for
round two) due to the detection of samples with detectable viral
loads that were below the set threshold for virologic failure.
Therefore, the positive predictive value of the assay decreased as
the threshold for virologic failure was raised when both rounds of
PCR were performed. Since two rounds of PCR did not offer an
advantage over one round for the detection of $1,000 HIV RNA
copies/mL and had a higher false positive rate, we hypothesize
that optimization of both assay sensitivity and positive predictive
value will be achieved more easily using one round of PCR,
although this should be validated in larger clinical cohorts. On one
hand, the use of pools contributes to a higher false positive rate,
but on the other hand it contributes to higher efficiency and lower
costs. The impact of each should be investigated further in settings
with a spectrum of different prevalence of virologic failure.
Concerning the detection of HIV-1 drug resistance, the PCR
products of all of the positive minipools were successfully
sequenced, and approximately one third of these harbored one
or more mutations conferring some degree of resistance to reverse
transcriptase inhibitors in one or both classes. When used in real
time, sequencing would be performed on the PCR product of
individual samples after deconvolution in order to give an
individualized account of virologic failure and drug resistance
profiles. Of course, these methods require laboratory settings with
technical expertise in PCR and sequencing, which already exist in
many resource-limited settings but are not used outside of the
research setting due to cost. This combined lower-cost method
would, therefore, allow for virologic monitoring and drug
resistance genotyping to be made available for routine patient
care in many of these areas and allow more informed decisions
regarding when to change ART.
A major limitation of this study was a low prevalence of
virologic failure among the study patients, of whom only four had
viral loads above 1,000 copies/mL. Since the objective of this
platform is to screen for levels of viremia likely to represent true
ART failure ($1,000 copies/mL), further evaluation using more
samples with viral loads within the range of interest is needed to
define the true sensitivity of the assay. Although the presented data
indicate that the sensitivity of this assay is close to the desired
target of at least one individual sample in the pool with 1,000 HIV
RNA copies/mL using only one round of PCR, this protocol may
require further optimization. For example, if the first-round PCR
does not prove effective in detecting pools with at least one sample
with $1,000 copies/mL in future applications, both rounds of
PCR may be used to screen the minipools. Alternatively, if the
assay is too sensitive, additional dilution with phosphate-buffered
Figure 2. Test characteristics of qualitative pooled RT assay in
the detection of varying levels of virologic failure using first
a n ds e c o n dr o u n d so fP C R .PPV=positive predictive value,
NPV=negative predictive value.
doi:10.1371/journal.pone.0035401.g002
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the desired sensitivity. Pool size may also be increased to lower
sensitivity and cost, or a combination of increased pool size and
further dilutions may be employed. The utility of these changes
would mostly depend upon local factors, such as the prevalence of
virologic failure in the population, the definition of virologic failure
used by national ART committees and policymakers, and the
number and frequency of samples screened. In addition, this study
used banked specimens with different storage times, and there is
the potential for RNA degradation in some samples that may have
affected the results, and screening in real-time would be helpful to
determine if this assay has the desired sensitivity or requires further
optimization. Finally, since this study was performed using samples
from a U.S. cohort, no patients infected with non-B subtypes were
included in the analysis. Although the PCR primers used in this
platform span a region in the RT coding region that is conserved
across clades, future experiments should focus on the predominant
infecting subtypes in the resource-limited settings that may benefit
from the proposed methods.
In conclusion, we present a platform that incorporates sample
pooling, PCR of the HIV-1 RT coding region and sequencing of
generated PCR product that can be used to screen for both
virologic failure of ART and drug resistance. Although further
optimization of assay sensitivity and evaluation on non-B HIV-1
subtypes are needed, the lower assay costs and ability to combine
virologic monitoring with drug resistance testing make it an
attractive alternative to commercial assays. If proven effective,
these methods would allow for maximization of first-line ART and
decrease complications associated with delayed detection of ART
failure in areas with limited resources for HIV services.
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